ASH_6.9_full issue | Page 36

THERE’S MORE TO
EXPLORE IN CLL
Visit CALQUENCEdata.com to see study results
CLL=chronic lymphocytic leukemia.
BTKi=Bruton tyrosine kinase inhibitor.
Indication and Usage
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)
or small lymphocytic lymphoma (SLL).
Select Safety Information
Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and
opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation
and flutter. The most common adverse reactions (≥ 30%) of any grade in patients with CLL were anemia,
neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.
Please see Brief Summary of Prescribing Information on adjacent pages.
CALQUENCE is a registered trademark of the AstraZeneca group of companies.
©2020 AstraZeneca. All rights reserved. US-37975 3/20